Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tecovirimat - SIGA Technologies

Next Previous
Drug Profile

Tecovirimat - SIGA Technologies

Alternative Names: Arestvyr; SIGA-246; ST-246 Form I (monohydrate); ST-246 Form V (hemihydrate); ST-246®; Tecovirimat - SIGA Technologies; Tecovirimat monohydrate - SIGA Technologies; Tecovirimat-SIGA; TPOXX

Latest Information Update: 21 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ViroPharma
  • Developer National Institute of Allergy and Infectious Diseases; SIGA Technologies
  • Class Antivirals; Benzamides; Cyclopropanes; Fluorinated hydrocarbons; Isoindoles; Organic bridged compounds; Small molecules
  • Mechanism of Action Orthopoxvirus p37 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Smallpox; Orthopoxvirus infections
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Smallpox
  • Registered Monkeypox; Orthopoxvirus infections; Vaccinia

Most Recent Events

  • 05 Mar 2025 U.S. Army Medical Research and Development Command completes a expanded access trial in Orthopoxvirus infections (In neonates, in infants, In the elderly, In children, In adults, In Adolescents) (IV, Infusion) (NCT05380752)
  • 02 Jan 2025 The PMDA approves tecovirimat for treatment of Vaccinia, Monkeypox and Smallpox (In adolescents, In adults, In children) in Japan (PO)
  • 02 Jan 2025 Registered for Monkeypox (In the elderly, In adults, In children, In adolescents) in Japan (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top